Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders.
Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand.
Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 7.0M |
| Three Month Average Volume | 197.0M |
| High Low | |
| Fifty-Two Week High | 127.74216 EUR |
| Fifty-Two Week Low | 94.06787 EUR |
| Fifty-Two Week High Date | 25 Jun 2024 |
| Fifty-Two Week Low Date | 19 Oct 2023 |
| Price and Volume | |
| Current Price | 112.38995 EUR |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.67% |
| Thirteen Week Relative Price Change | -11.84% |
| Twenty-Six Week Relative Price Change | -15.15% |
| Fifty-Two Week Relative Price Change | -13.26% |
| Year-to-Date Relative Price Change | -8.25% |
| Price Change | |
| One Day Price Change | 0.84% |
| Thirteen Week Price Change | -5.65% |
| Twenty-Six Week Price Change | -6.70% |
| Five Day Price Change | 1.59% |
| Fifty-Two Week Price Change | 8.69% |
| Year-to-Date Price Change | 8.65% |
| Month-to-Date Price Change | 4.70% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 14.0851 EUR |
| Book Value Per Share (Most Recent Quarter) | 16.30836 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.60979 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.03452 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 11.55383 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 22.39476 EUR |
| Revenue Per Share (Trailing Twelve Months) | 23.39714 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 2.80856 EUR |
| Dividend Per Share (Trailing Twelve Months) | 2.88447 EUR |
| Dividend Per Share (5 Year) | 2.49355 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.13598 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | 5.11389 EUR |
| Normalized (Last Fiscal Year) | 5.39052 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.13651 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 5.13589 EUR |
| Including Extraordinary Items (Last Fiscal Year) | 0.13598 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | 5.11389 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.65841 EUR |
| Cash Per Share (Most Recent Quarter) | 4.24866 EUR |
| Cash Flow Per Share (Last Fiscal Year) | 1.58289 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | 6.68297 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | 2.06113 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 7 |
| Cash Flow Revenue (Trailing Twelve Months) | 9 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 24.41% |
| Pretax Margin (Last Fiscal Year) | 3.14% |
| Pretax Margin (5 Year) | 18.19% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 73.53% |
| Gross Margin (Trailing Twelve Months) | 75.79% |
| Gross Margin (5 Year) | 72.26% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 2.97% |
| Operating Margin (Trailing Twelve Months) | 24.75% |
| Operating Margin (5 Year) | 17.91% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 0.63% |
| Net Profit Margin (Trailing Twelve Months) | 22.01% |
| Net Profit Margin (5 Year) | 15.03% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 7.59% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -11.54% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 7.16% |
| Revenue Growth (3 Year) | 7.29% |
| Revenue Change (Trailing Twelve Months) | 7.15% |
| Revenue Per Share Growth | 8.38% |
| Revenue Growth (5 Year) | 13.13% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 8.12% |
| Total Debt (5 Year) | 6.90% |
| Dividends | |
| Dividend Growth (3 Year) | 6.08% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 191.12% |
| EPS Change (Trailing Twelve Months) | 342.24% |
| EPS Growth (3 Year) | -43.23% |
| EPS Growth (5 Year) | -56.81% |
| EBITDA | |
| EBITDA (5 Year) | 7.35% |
| EBITDA (5 Year Interim) | 9.39% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -47.23% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 55 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 177 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 55 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 26.4B |
| Net Debt (Last Fiscal Year) | 28.0B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 22 |
| PE Normalized (Last Fiscal Year) | 21 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 23 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 836 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 14 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 22 |
| Dividends | |
| Dividend Yield (5 Year) | 2.85% |
| Dividend Yield | 2.60% |
| Current Dividend Yield | 2.57% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 8 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 90 |
| Long Term Debt to Equity (Most Recent Quarter) | 80 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 2,068.77% |
| Payout Ratio (Trailing Twelve Months) | 56.40% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 49 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 1.7B |
| Free Cash Flow (Trailing Twelve Months) | 5.5B |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 28 |
| Net Interest Coverage (Trailing Twelve Months) | 25 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 93 |
| Total Debt to Equity (Most Recent Quarter) | 87 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 0.35% |
| Return on Assets (Trailing Twelve Months) | 12.67% |
| Return on Assets (5 Year) | 7.70% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 0.87% |
| Return on Equity (Trailing Twelve Months) | 33.39% |
| Return on Equity (5 Year) | 22.35% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 0.45% |
| Return on Investment (Trailing Twelve Months) | 16.42% |
| Return on Investment (5 Year) | 10.29% |